The long-range goals of the proposed research are to identify the components of the anion-selective pore of the cystic fibrosis transmembrane conductance regulator (CFTR), to understand the physical basis for anion conduction and to discover the moving parts of the anion conduction pathway. Anion conduction through the CFTR chloride channel is a key element in two devastating diseases, cystic fibrosis and secretory diarrhea. Modifying CFTR channel activity could significantly impact therapies, but neither the structural basis for anion conduction nor the role of the transmembrane segments in gating has been fully defined. Covalent labeling of engineered cysteines has been used to identify elements of the anion conduction pathway of CFTR, but three factors limit the utility of this approach. First, conventional thiol-directed reagents cannot probe the narrowest portion of the pore. Second, our recent results identify spontaneous and potentially confounding reactions of cysteine thiols not fully appreciated in previous studies. Third, the lack of an atomic- scale model for the pore has prevented any realistic understanding of the physical basis for anion conduction. Our recent work suggests new approaches. We have demonstrated that the permeant, pseudohalide anions, [Au(CN)2]- and [Ag(CN)2]- can be locked inside the CFTR pore by means of a ligand substitution reaction. These permeant probes have provided access to engineered cysteines that are invisible to more conventional reagents. Cysteines substituted at these conformationally restricted sites exhibit dramatic changes in reactivity that correlate with the channel gating state. We have also carried out the first exhaustive survey of the reactivity of cysteines engineered into CFTR and defined spontaneous reactions that dramatically alter thiol reactivity. We have implemented an expanded panel of thiol-reactive reagents that will be used to chemically fingerprint engineered cysteines and control for confounding thiol reactions. Finally, collaboration with Mark Sansom has resulted in the first atomic-scale, homology models for the CFTR pore.
The specific aims of the proposed research are: 1. To operationally define different regions of the conduction path by comparing quantitatively the reactivity of substituted cysteines toward a panel of permeant and impermeant, thiol-reactive probes differing in size, charge, and reaction mechanism. 2. To identify a subset of conformationally restricted, engineered cysteines that exhibit reactivity that is dependent on the gating state of the channel. 3. To identify sites within the CFTR anion conduction pathway where the rate of covalent labeling is altered by the presence of a pore-blocking, small molecule. 4. To refine an atomic-scale model for CFTR based on the prokaryotic homologues, MsbA and Sav1866 and a two-dimensional EM map of CFTR, utilizing an iterative process of molecular modeling, quantitative model predictions and experimental testing;and to use this model to define the physical basis for anion conduction.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK045880-18
Application #
7866617
Study Section
Membrane Biology and Protein Processing (MBPP)
Program Officer
Mckeon, Catherine T
Project Start
1992-09-30
Project End
2013-06-30
Budget Start
2010-07-01
Budget End
2013-06-30
Support Year
18
Fiscal Year
2010
Total Cost
$416,298
Indirect Cost
Name
Oregon Health and Science University
Department
Physiology
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Moran, A R; Norimatsu, Y; Dawson, D C et al. (2014) Aqueous cigarette smoke extract induces a voltage-dependent inhibition of CFTR expressed in Xenopus oocytes. Am J Physiol Lung Cell Mol Physiol 306:L284-91
Liu, Xuehong; Dawson, David C (2014) Cystic fibrosis transmembrane conductance regulator (CFTR) potentiators protect G551D but not ?F508 CFTR from thermal instability. Biochemistry 53:5613-8
Norimatsu, Yohei; Ivetac, Anthony; Alexander, Christopher et al. (2012) Cystic fibrosis transmembrane conductance regulator: a molecular model defines the architecture of the anion conduction path and locates a ""bottleneck"" in the pore. Biochemistry 51:2199-212
Norimatsu, Yohei; Ivetac, Anthony; Alexander, Christopher et al. (2012) Locating a plausible binding site for an open-channel blocker, GlyH-101, in the pore of the cystic fibrosis transmembrane conductance regulator. Mol Pharmacol 82:1042-55
Liu, Xuehong; O'Donnell, Nicolette; Landstrom, Allison et al. (2012) Thermal instability of ýýF508 cystic fibrosis transmembrane conductance regulator (CFTR) channel function: protection by single suppressor mutations and inhibiting channel activity. Biochemistry 51:5113-24
Norimatsu, Yohei; Moran, Aurelia R; MacDonald, Kelvin D (2012) Lubiprostone activates CFTR, but not ClC-2, via the prostaglandin receptor (EP(4)). Biochem Biophys Res Commun 426:374-9
Liu, Xuehong; Dawson, David C (2011) Cystic fibrosis transmembrane conductance regulator: temperature-dependent cysteine reactivity suggests different stable conformers of the conduction pathway. Biochemistry 50:10311-7
Alexander, Christopher; Ivetac, Anthony; Liu, Xuehong et al. (2009) Cystic fibrosis transmembrane conductance regulator: using differential reactivity toward channel-permeant and channel-impermeant thiol-reactive probes to test a molecular model for the pore. Biochemistry 48:10078-88
Liu, Xuehong; Alexander, Christopher; Serrano, Jose et al. (2006) Variable reactivity of an engineered cysteine at position 338 in cystic fibrosis transmembrane conductance regulator reflects different chemical states of the thiol. J Biol Chem 281:8275-85
Weber, Gerhard J; Mehr, Ali Poyan; Sirota, Jeffrey C et al. (2006) Mercury and zinc differentially inhibit shark and human CFTR orthologues: involvement of shark cysteine 102. Am J Physiol Cell Physiol 290:C793-801

Showing the most recent 10 out of 21 publications